The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Characteristics and clinical outcomes among patients receiving either ibrutinib or anti-CD20 monotherapy as first-line (1L) treatment for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): A retrospective analysis in community oncology practice.
 
Julie Vose
Honoraria - Acerta Pharma/AstraZeneca; Conjupro Biotherapeutics; Johnson and Johnson; Lilly; MEI Pharma; Morphosys; Oncternal Therapeutics; Roche/Genentech
Research Funding - Acerta Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Epizyme; Incyte (Inst); Kite, a Gilead company (Inst); Loxo; Novartis (Inst); Seagen (Inst)
 
Jinghua He
Employment - Janssen Scientific Affairs
Stock and Other Ownership Interests - Johnson and Johnson; Merck
 
Xiaoxiao Lu
Employment - Janssen
Stock and Other Ownership Interests - Janssen
Travel, Accommodations, Expenses - Janssen
 
Linda Wu
Employment - Janssen
Stock and Other Ownership Interests - Janssen
Patents, Royalties, Other Intellectual Property - Janssen
 
Tao Ran
Employment - Janssen
Stock and Other Ownership Interests - Janssen
Travel, Accommodations, Expenses - Janssen
 
Sumeet Panjabi
Employment - Janssen
Stock and Other Ownership Interests - Amgen; FibroGen; Inovio Pharmaceuticals; Janssen; Moderna Therapeutics
Travel, Accommodations, Expenses - Janssen